[Clinical tests of a new corticoid for topical use: Nerisona].
Diflucortolone valerate 0.1% (Nerisona), a new topical corticoid, was clinically investigated in ointment form in 51 patients suffering from neither weeping nor very dry allergic and inflammatory skin diseases. The results obtained were good, improvement being observed in 92.1% of the treated cases. The cosmetic properties of the preparation were excellent. No local or systemic side effects were observed.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005448:Fluocortolone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011244:Pregnadienediols / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*; D014631:Valerates / Q000627:therapeutic use
D011244:Pregnadienediols; D014631:Valerates; D005448:Fluocortolone
Klinische Prüfung mit einem neuen Kortikoid zur topischen Anwendung: Nerisona